Compare Amphastar Pharmaceuticals Inc (AMPH) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Colgate-Palmolive Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Colgate-Palmolive Company trades at $92.91 (market cap $73.81B). The key difference: Colgate-Palmolive Company is far larger — about 89.3× Amphastar Pharmaceuticals Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CL | |
|---|---|---|
Market Cap | $826.08M | $73.81B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $99.14 |
52-Week Low | $16.87 | $74.98 |
Enterprise Value | $1.22B | $80.45B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Colgate-Palmolive (CL) trades at $92.24, up 1.35% on the day, reflecting strong momentum with a bullish technical signal and consistent earnings beats. The company maintains robust profitability with a 60.06% gross margin and 10.04% net income margin, though its P/E of 35.75 and P/B of 509.03 indicate premium valuation. Recent news highlights its status as a Dividend King with a 64-year streak, supported by stable cash flow from operations of $4.20B in 2025.
Outlook remains positive with analyst consensus target of $95.56, but risks include North American segment softness and inflationary pressures. The stock offers income stability through dividends, yet high valuation multiples may limit near-term upside absent accelerated growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
